Despite Progress, More Actionable Mutations Needed in Lung Cancer
December 2nd 2016Despite these successes, driver mutations have been identified in only a minority of cases and patients with other types of lung cancer, such as squamous cell carcinoma and small-cell lung cancer, do not currently benefit from targeted therapies.
Moving the Meter on Ovarian Cancer
December 2nd 2016Ovarian cancer remains a silent and deadly tumor type with 5-year survival rates that lag far behind those of other gynecologic malignancies. Yet optimism is in the air these days as researchers focus on developing new therapies in 2 key areas: antiangiogenic agents and PARP inhibitors.
Checkpoint Inhibitors Changing Landscape for Advanced Solid Tumors
November 29th 2016Immunotherapy continues to be one of the fastest-evolving fields in oncology. In recent years, numerous immunotherapies have shown good efficacy, safety, and durability across many tumor types, including some advanced solid tumors that have not seen meaningful treatment developments in decades.
Novel Agent Aims to Improve HCT Outcomes in High-Risk AML
November 23rd 2016A clinical trial that utilizes a novel radiolabeled antibody–drug conjugate to pretreat older patients with relapsed or refractory acute myeloid leukemia as part of a stem cell transplantation regimen is aimed at creating improved outcomes for a high-risk population with limited therapeutic alternatives.
New Imaging Strategies for Prostate Cancer Explored
November 23rd 2016Continuing research will have to evaluate whether combining serum biomarkers or other measurable clinical factors with multiparametric magnetic resonance imaging results can help make negative or inaccurate prostate biopsies a rarity rather than the norm.
When Well-Meaning Health Policy Goes Awry
November 23rd 2016Those responsible for developing and implementing governmental health policy have an extremely difficult job. Not only do they have to attempt to satisfy often highly unrealistic expectations of legislators for overall goals and timelines, but they also are frequently asked to accomplish a task with woefully inadequate funding.
"Advancing Hope": SITC Designs Innovative Educational Experience for the Management of NSCLC
November 23rd 2016Lung cancer alone accounts for 26.5% of all cancer-related mortalities in the United States, which is more than any other malignancy. Despite increased awareness that smoking is an important risk factor for lung cancer, which has reduced the number of smokers in the U.S., nearly a quarter of a million new diagnoses are expected in 2016.